Study of Xarelto for DVT and PE published in Thrombosis

A pooled analysis of the Phase III EINSTEIN trial program, shows Xarelto (rivaroxaban), from Janssen/Bayer HealthCare, is as effective as the standard of care in reducing the risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

The analysis also found safety and efficacy outcomes for Xarelto were consistent across four subgroups of participants: fragile subjects, those with cancer, subjects with a history of a recurrent venous thromboembolism (VTE) and those presenting with a large clot. These findings were published in Thrombosis Journal. See: "Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies." Martin H Prins et al. Thrombosis Journal 20 September 2013, 11:21 doi:10.1186/1477-9560-11-21